In context
Ibutamoren, also called MK-677, is a non-peptide growth-hormone secretagogue. Short clinical experiments examined nitrogen balance during caloric restriction and hormone responses in children with growth-hormone deficiency. [1–2]
At a glance
- Type
- Non-peptide compound / mimetic
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- These small, short studies do not establish sustained functional improvement or long-term safety. Being grouped with peptides in marketing does not make it a peptide.
How to interpret this evidence
These small, short studies do not establish sustained functional improvement or long-term safety. Being grouped with peptides in marketing does not make it a peptide. [1] [2]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. pubmed.ncbi.nlm.nih.gov
- Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. pubmed.ncbi.nlm.nih.gov